NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
Stock Information for iCad Inc.
Loading
Please wait while we load your information from QuoteMedia.